唑来磷酸治疗老年骨质疏松症18例的骨痛缓解及安全性观察  

Observation on Pain Relief and Safety of Zoledronic acid for the Treatment of 18 Elderly Patients with Osteoporosis

作　　者：陆守荣[1] 王滨[1] 万鹤鸣[1] 张炳山[1] 郭华[1] 王卓[1] 郁洁[1] 

机构地区：[1]南京医科大学附属无锡人民医院老年医学科,江苏无锡214023

出　　处：《医学临床研究》2012年第10期1916-1918,共3页Journal of Clinical Research

摘　　要：【目的】观察唑来磷酸治疗老年骨质疏松症的缓解疼痛的效果及安全性。【方法】应用唑来磷酸注射液治疗18例65-85岁老年骨质疏松症患者，观察治疗前后患者骨痛的缓解情况，血钙、磷、碱性磷酸酶变化及不良反应情况，采用双能x线骨密度仪测定患者治疗前后骨密度变化。【结果】治疗后患者骨痛症状明显改善，血钙、磷无显著变化（P〉0．05），血碱性磷酸酶明显下降（P〈0．05），骨密度较治疗前显著增加（P〈0．01，P〈0．05），18例患者不良反应发生率为56．0％，但患者能耐受。【结论】唑来磷酸是治疗老年性骨质疏松症的安全有效性药物。[Objective] To observe the pain relief efficacy and safety of zoledronic acid for the treatment of elderly patients with osteoporosis. [Methods] Eighteen elderly patients with osteoporosis（aged from 65 to 85 years old） were treated with zoledronic acid. The bone pain relief, the changes of serum calcium, phosphate and alkalinephosphatase and adverse reaction before and after treatment were observed. Dual energy X-ray absorptionmetry（DXA） was used to measure the change of bone mineral density（BMD） before and after treatment. [Results] The symptom of bone pain of patients after treatment was significantly improved, and serum calcium and phosphate showed no significant change （ P 〉0.05 ）, and serum alkalinephosphatase obviously decreased （ P〈0. 05）. Compared with before treatment, BMD significantly increased after treatment（ P〈0.01, P〈0.05）. The incidence of adverse reactions of 18 patients was 56. 0%, and all patients could tolerate them. [Conclusion] Zoledronic acid is an effective and safe drug for the treatment of elderly patients with osteoporosis.

关 键 词：骨质疏松 药物疗法 骨质疏松 并发症 疼痛 药物疗法 

分 类 号：R681[医药卫生—骨科学]